Foundayo (orforglipron) Approved: The First Once-Daily Oral GLP-1 Pill for Weight Loss

On April 1, 2026, the FDA approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 pill, for chronic weight management in adults with obesity or overweight with weight-related medical problems [1]. Foundayo is the first non-peptide, small-molecule GLP-1 receptor agonist ever approved for weight loss. Unlike Rybelsus (oral semaglutide), which is a peptide formulated with an absorption enhancer and must be taken on an empty stomach with strict water restrictions, Foundayo is a true small molecule that can be taken any time of day with or without food. This is a material change to the dosing experience and the GLP-1 access story. We walk through the verified ATTAIN-1 phase 3 trial data, the dosing schedule, the launch pricing, the safety profile, and how Foundayo compares head-to-head with the injectable semaglutide and tirzepatide already on the market.

What Foundayo is, mechanically

Foundayo (generic name orforglipron, internal designation LY3502970) is a small-molecule, non-peptide GLP-1 receptor agonist [1]. The distinction between “small-molecule” and “peptide” matters because peptides are digested in the stomach. Every existing FDA-approved GLP-1 agonist (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) is a peptide, and that's why all of them are injectable — except for Rybelsus (oral semaglutide), which gets around the digestion problem with a special absorption enhancer (SNAC) and requires the patient to take it on an empty stomach with no more than 4 ounces of water and then wait 30 minutes before eating, drinking, or taking other oral medications.

Orforglipron isn't a peptide at all. It's a small organic molecule that binds and activates the GLP-1 receptor directly, with the same downstream effects on appetite, gastric emptying, and reward circuitry that injectable semaglutide produces. Because it's a small molecule, it survives stomach acid and digestion, doesn't require food restrictions, and produced predictable pharmacokinetics across the food-effect study published in Diabetes Therapy in 2024 [2]. Orforglipron was originally discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018 [1].

The ATTAIN-1 phase 3 trial

Foundayo's approval is anchored on the ATTAIN-1 phase 3 trial (NCT05869903) [1, 3]. Verified design parameters:

• Sample size: 3,127 adults randomized
• Population: Adults with obesity, or overweight with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) — and importantly, without diabetes. The diabetes population is being studied separately in ATTAIN-2.
• Design: Phase 3, randomized, double-blind, placebo-controlled, multi-dose
• Duration: 72 weeks
• Geography: 10 countries — US, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain, and Taiwan
• Primary endpoint: Percent change in body weight from baseline at week 72

The headline efficacy

Two estimands were reported in the Lilly approval press release. The efficacy estimand represents what happens to participants who stayed on study drug for the full 72 weeks. The treatment-regimen estimand represents the average effect across all randomized participants regardless of whether they stuck with treatment. Both are clinically informative; the treatment-regimen estimand is closer to a real-world prescribing experience [1]:

Foundayo also produced reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses tested in the ATTAIN program [1].

How Foundayo compares to injectable GLP-1s

The comparison most patients will want to make: Foundayo vs Wegovy (semaglutide 2.4 mg weekly) vs Zepbound (tirzepatide 15 mg weekly). These are not direct head-to-head trials — they're separate trials with different populations and designs — but the trial-arm magnitudes give a useful framing:

Foundayo's effect size sits below injectable semaglutide and well below tirzepatide. That's the trade-off the patient and prescriber need to weigh against the convenience of a daily pill that doesn't require injection technique, cold-chain shipping, or a sharps container. For patients who will not or cannot use an injectable — needle phobia is a meaningful barrier — Foundayo is now a real option backed by a large randomized trial. For patients optimizing for maximum weight loss, the injectables remain the higher-magnitude choice. See our tirzepatide vs semaglutide deep-dive for the injectable comparison.

Dosing and titration

Foundayo is a once-daily oral tablet available in six strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg [1]. Tablets are swallowed whole — not broken, crushed, or chewed — and can be taken any time of day with or without food and with no water restrictions. Dose escalation follows a graduated schedule from the lowest strength upward, consistent with the GI-tolerability strategy used by all modern GLP-1 agonists. Like semaglutide and tirzepatide, Foundayo cannot be combined with other GLP-1 receptor agonist medications.

Safety and the boxed warning

Foundayo carries the same boxed warning as every other FDA-approved GLP-1 receptor agonist: thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), have been observed in rodent studies, and the drug is contraindicated in patients with personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]. The most common adverse events reported in the ATTAIN trials were the standard GLP-1 GI side effects (nausea, constipation, diarrhea, vomiting, abdominal pain, indigestion, belching, heartburn) plus headache, swollen belly, fatigue, gas, and hair loss [1]. For a detailed comparison of the GI side effect profile across the GLP-1 class, see our side effects investigation.

Other label warnings consistent with the GLP-1 class: pancreatitis, dehydration-induced kidney problems, gallbladder disease, hypoglycemia (particularly in patients on insulin or sulfonylureas), serious allergic reactions, diabetic retinopathy progression in patients with type 2 diabetes, and increased risk of food/liquid aspiration during anesthesia [1].

Pricing — the most important practical detail

Foundayo is launching through Lilly's direct-to-patient platform, LillyDirect, with shipping beginning April 6, 2026, followed by broader retail and telehealth availability shortly after [1]. The pricing structure is the most important access change in the GLP-1 market in 2026:

• Commercial insurance coverage: as low as $25 per month with the Foundayo savings card
• Self-pay: $149 per month for the lowest dose
• Medicare Part D (eligible): as low as $50 per month, beginning July 1, 2026

For comparison, the cash price of Wegovy in early 2026 ranged from roughly $1,300 to $1,400 per month before rebates and savings cards; Zepbound cash pricing was in a similar range. The $149 self-pay floor for Foundayo is roughly an order of magnitude lower than the existing injectable cash prices. For the live state of compounded and brand-name GLP-1 pricing across the telehealth market, see our pricing index.

What this means for patients

Foundayo changes the GLP-1 access conversation in three practical ways:

1. Needle removal. A meaningful fraction of patients who could benefit from GLP-1 therapy refuse or discontinue the injectables because of injection burden or needle phobia. Foundayo gives those patients a first-line, FDA-approved oral option backed by a large randomized trial — at the cost of about 2-3 percentage points of weight loss versus injectable semaglutide.
2. Cash-pay floor at $149/month. Lilly is using Foundayo to compete on price as well as convenience. The $149 self-pay tier puts a branded, FDA-approved GLP-1 inside the cash-pay range that, until now, was occupied almost entirely by compounded semaglutide and tirzepatide from telehealth providers. We expect this to materially reshape the compounded market.
3. Pipeline implications. Orforglipron is also being studied for type 2 diabetes (ATTAIN-2), obstructive sleep apnea, knee osteoarthritis, hypertension, peripheral artery disease, and stress urinary incontinence [1]. If those indications read out positive, the small- molecule GLP-1 footprint will expand substantially over the next 2-3 years.

Open questions

1. Long-term durability. ATTAIN-1 was 72 weeks. Whether the weight loss is maintained after that point — and whether the post-discontinuation regain pattern documented for injectable semaglutide (see our STEP-4 / STEP-1 extension review) also applies to oral orforglipron — has not been published.
2. Cardiovascular outcomes. Foundayo's approval is for chronic weight management. A SELECT-style cardiovascular outcomes trial in non-diabetic patients with established cardiovascular disease has not been announced. For the injectable semaglutide cardiovascular evidence, see our SELECT trial deep-dive.
3. Direct head-to-head data. No published trial has directly compared orforglipron to injectable semaglutide or tirzepatide in the same population on the same protocol. The trial-arm comparisons in this article are indirect.

Related research

For our broader coverage of the GLP-1 landscape, see the pricing index, the side-effects investigation, the SELECT cardiovascular trial deep-dive, the FLOW kidney trial deep-dive, and the tirzepatide vs semaglutide head-to-head.